CD4 and neoplasm: The PMA formulation efficiently delivered tumor vaccines and sustained neoantigen presentation to APCs to achieve a long-term immune response, triggering systemic immunity against tumor neoantigens and promoting infiltration of functional immune cells, such as CD8+ T, CD4+ T, and B cells, to inhibit both MC38 and 4T1 tumor growth.